Application of the genO-hOX40 mouse model

Useful applications for researchers working on different biomedical fields, such as immuno-inflammation, oncology and autoimmunity:

  • Assess the efficacy of OX40-targeting compounds
    • Performe tumor growth inhibition assays
    • Evaluate OX40 antagonists for the treatment of autoimmune and inflammatory conditions
  • Gain insights into the mode of action (MoA) of diverse constructs and their potential therapeutic benefits
  • Perform long-term studies, as immunological memory is observed following treatment

Features

  • Physiological regulation and expression pattern of the human OX40
  • Preservation of the target-ligand interaction
  • Fully functional mouse immune system
  • Lack of expression of the murine target gene, thus avoiding cross-reactivity

Anti-tumor efficacy and tumor-specific immunological memory were proven in MC38 and MB49 tumor models.

Clients

No items found.

Access to models

  • Breeding facilities in US and Europe
  • Certified health status from professional breeders
  • Delivery door-to-door worldwide

Related resources and publications

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No results

Validation data

Discover related products to

genO-hOX40

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
CD47
SIRPα
ICP (single-target)
ICP (multi-target)
Immune checkpoint

genO-hCD47/hSIRPα

Double-humanized genO‑hCD47/hSIRPα immunocompetent mice enable the efficacy assessment of anti-CD47/SIRPα.

Immune checkpoint
CTLA-4
ICP (single-target)

genO-hCTLA‑4

The genO‑hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
Lag3
ICP (multi-target)

genO-hCTLA‑4/hLAG3

The genO‑hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
PD-1
ICP (multi-target)

genO-hPD‑1/hCTLA‑4

The genO‑hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

Immune checkpoint
PD-1
GITR
ICP (multi-target)
GITRL

genO-hPD‑1/hGITR/hGITRL

The genO-hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

Immune checkpoint
PD-1
PD-L1
ICP (multi-target)

genO-hPD‑1/hPD‑L1

The genO‑hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

Immune checkpoint
PD-1
TIM3
ICP (multi-target)

genO-hPD‑1/hTIM3

The genO‑hPD‑1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

Immune checkpoint
PD-1
VISTA
ICP (multi-target)

genO-hPD‑1/hVISTA

The genO‑hPD‑1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

CD137
ICP (single-target)
Immune checkpoint

genO‑hCD137

genO‑hCD137 immunocompetent mice enable the efficacy assessment of anti-CD137.

Immune checkpoint
CD28
ICP (single-target)
T-cell engager

genO‑hCD28

The genO‑hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

Immune checkpoint
CD39
ICP (single-target)

genO‑hCD39

The genO‑hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

Immune checkpoint
GITR
ICP (single-target)

genO‑hGITR

The genO‑hGITR mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR in fully immunocompetent mice.

Immune checkpoint
GITR
GITRL
ICP (multi-target)

genO‑hGITR/hGITRL

The genO‑hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of agonist and antagonist antibodies targeting human immune checkpoint GITR and/or GITRL in fully immunocompetent mice.

PD-1
Immune checkpoint
ICP (single-target)

genO‑hPD‑1

The genO‑hPD‑1 mouse enables the in vivo efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice

Immune checkpoint
PD-1
Lag3
ICP (multi-target)

genO‑hPD‑1/hLAG3

The genO‑hPD‑1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
VISTA
ICP (single-target)

genO‑hVISTA

The genO‑hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.

Preclinical humanized genO-hOX40 mouse model

Get in touch about

Let us know how we can help